The FDA is moving to fill vacancies on its advisory committees, the expert panels that advise on regulatory decisions. The recruitment push is aimed at bringing new scientific and consumer voices to the panels, according to MedCity News.
The advisory committees, informally known as adcomms, met less frequently during the Trump administration. However, the report notes that more meetings have been scheduled since former Commissioner Marty Makary departed the agency in May.
The source does not specify how many vacancies exist or which committees are affected, and no further details on the recruitment timeline were provided. This article is based on a single report, so no independent verification or contrasting sources were available.